Kenneth P Olive

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4020290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High-speed light-sheet microscopy for the in-situ acquisition of volumetric histological images of living tissue. Nature Biomedical Engineering, 2022, 6, 569-583.	11.6	28
2	Enteroendocrine Cell Formation Is an Early Event in Pancreatic Tumorigenesis. Frontiers in Physiology, 2022, 13, 865452.	1.3	3
3	The vascular landscape of human cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	26
4	PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. JCI Insight, 2021, 6, .	2.3	7
5	Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic Cancer. Cancers, 2021, 13, 1535.	1.7	3
6	lsoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Molecular Therapy, 2021, 29, 1557-1571.	3.7	25
7	HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. Journal of Clinical Investigation, 2021, 131, .	3.9	105
8	Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. Journal of Clinical Investigation, 2021, 131, .	3.9	144
9	GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nature Communications, 2021, 12, 4860.	5.8	131
10	Abstract PO-120: Differential expression of polyamine pathways in human pancreatic tumor progression and effects of polyamine blockade therapy on the in vivo pancreatic tumor microenvironment. , 2021, , .		0
11	Abstract PR-014: Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1. , 2021, , .		0
12	Abstract PO-033: Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. , 2021, , .		0
13	Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment. Cancers, 2021, 13, 6391.	1.7	18
14	Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2. Gastroenterology, 2020, 159, 1866-1881.e8.	0.6	45
15	CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 6051-6063.	3.2	14
16	A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer. Cancer Research, 2020, 80, 4754-4767.	0.4	37
17	Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte–mediated immune suppression. Gut, 2020, 70, gutjnl-2019-319912.	6.1	32
18	HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. Experimental Cell Research, 2020, 390, 111960.	1.2	10

KENNETH P OLIVE

#	Article	IF	CITATIONS
19	Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science, 2020, 368, 85-89.	6.0	692
20	Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Genome Research, 2020, 30, 347-360.	2.4	47
21	Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) <i>in vivo</i> . Theranostics, 2020, 10, 4614-4626.	4.6	33
22	Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. Clinical Cancer Research, 2020, 26, 1297-1308.	3.2	30
23	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Research, 2019, 79, 4491-4502.	0.4	27
24	The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature Communications, 2019, 10, 4682.	5.8	123
25	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984123.	1.4	35
26	Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 5548-5560.	3.2	23
27	Modeling Pancreatic Cancer through Somatic Editing with AAV. Trends in Molecular Medicine, 2019, 25, 361-362.	3.5	Ο
28	Precision Medicine in Pancreatic Disease—Knowledge Gaps and Research Opportunities. Pancreas, 2019, 48, 1250-1258.	0.5	9
29	Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Translational Research, 2019, 207, 56-69.	2.2	35
30	Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut, 2019, 68, 1034-1043.	6.1	147
31	Laser Capture Microdissection on Frozen Sections for Extraction of High-Quality Nucleic Acids. Methods in Molecular Biology, 2019, 1882, 253-259.	0.4	15
32	Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut, 2019, 68, 499-511.	6.1	39
33	β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell, 2018, 33, 75-90.e7.	7.7	287
34	Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discovery, 2018, 8, 1458-1473.	7.7	158
35	Technical Note: <i>In vivo</i> Young's modulus mapping of pancreatic ductal adenocarcinoma during <scp>HIFU</scp> ablation using harmonic motion elastography (<scp>HME</scp>). Medical Physics, 2018, 45, 5244-5250.	1.6	9
36	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	13.5	213

KENNETH P OLIVE

#	Article	IF	CITATIONS
37	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
38	Notice of Removal: Pancreatic ductal adenocarcinoma detection and treatment monitoring in vivo and in post-surgical human specimens using Harmonic Motion Imaging (HMI). , 2017, , .		0
39	Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy. Journal of Oncology Practice, 2017, 13, 181-183.	2.5	5
40	Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell Stem Cell, 2016, 18, 441-455.	5.2	196
41	Elasticity mapping of murine abdominal organs <i>in vivo</i> using harmonic motion imaging (HMI). Physics in Medicine and Biology, 2016, 61, 5741-5754.	1.6	22
42	Stroma, Stroma Everywhere (Far More Than You Think). Clinical Cancer Research, 2015, 21, 3366-3368.	3.2	16
43	Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2015, 62, 1662-1673.	1.7	33
44	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research, 2015, 21, 2096-2106.	3.2	48
45	Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Carcinogenesis, 2015, 36, 730-738.	1.3	29
46	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Science Translational Medicine, 2015, 7, 271ra7.	5.8	236
47	Translational Therapeutics in Genetically Engineered Mouse Models of Cancer. Cold Spring Harbor Protocols, 2014, 2014, pdb.top069997.	0.2	10
48	Acquisition of Mouse Tumor Biopsies through Abdominal Laparotomy. Cold Spring Harbor Protocols, 2014, 2014, pdb.prot077834.	0.2	7
49	Identification and Manipulation of Biliary Metaplasia in Pancreatic Tumors. Gastroenterology, 2014, 146, 233-244.e5.	0.6	118
50	Protein breakdown precedes pancreatic tumor development. Nature Medicine, 2014, 20, 1097-1099.	15.2	8
51	Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2014, 25, 735-747.	7.7	1,616
52	Quantification of Murine Pancreatic Tumors by High-Resolution Ultrasound. Methods in Molecular Biology, 2013, 980, 249-266.	0.4	47
53	Recapitulating human cancer in a mouse. Nature Biotechnology, 2013, 31, 392-395.	9.4	7
54	Pancreatic cancer: why is it so hard to treat?. Therapeutic Advances in Gastroenterology, 2013, 6, 321-337.	1.4	250

KENNETH P OLIVE

#	Article	IF	CITATIONS
55	Genetically Engineered Mouse Models of Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 502-510.	1.0	90
56	Silencing the Killers: Paracrine Immune Suppression in Pancreatic Cancer. Cancer Cell, 2012, 21, 715-716.	7.7	13
57	Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate Blood, 2012, 120, 2758-2758.	0.6	1
58	Stromal biology and therapy in pancreatic cancer. Gut, 2011, 60, 861-868.	6.1	652
59	A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy. Cancer Chemotherapy and Pharmacology, 2011, 68, 1243-1253.	1.1	48
60	Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer. Cancer Cell, 2010, 18, 499-509.	7.7	147
61	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	6.0	2,730
62	Heterozygosity for <i>Hypoxia Inducible Factor 1α</i> Decreases the Incidence of Thymic Lymphomas in a p53 Mutant Mouse Model. Cancer Research, 2009, 69, 3213-3220.	0.4	33
63	Kâ€Rasâ€Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor Analyses. Methods in Enzymology, 2008, 439, 73-85.	0.4	26
64	The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics. Clinical Cancer Research, 2006, 12, 5277-5287.	3.2	218
65	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.4	488
66	Mice Expressing a Mammary Gland–Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.4	59
67	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	13.5	1,140